Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novartis reports first data from 3-year phase III SMC-021 study

Nov. 15, 2011

Eli Lilly and Boehringer Ingelheim begin phase III trials of LY-2605541

Nov. 15, 2011

Scientists at Roche prepare novel vasopressin V1A receptor antagonists

Nov. 15, 2011

FDA schedules review of NDA for progesterone vaginal gel

Nov. 14, 2011

Scientists at Janssen synthesize new ketohexokinase inhibitors

Nov. 14, 2011

Novel clinical data and analyses presented on Regeneron's rilonacept

Nov. 14, 2011

FDA releases safety communication on Trilipix

Nov. 11, 2011

New cytochrome P450 19A1 inhibitors patented in U.S.

Nov. 11, 2011

Phase II data on FG-4592 presented at Kidney Week

Nov. 11, 2011

Sanofi and Regeneron report on phase II hypercholesterolemia program

Nov. 10, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...